People with diabetes who smoke face a compounded set of health risks that make the harm reduction argument for switching to vaping particularly compelling in this population. But the question of whether vaping is safe — or at least safer than smoking — for people with diabetes requires a more nuanced answer than the general population guidance provides. A visit to a knowledgeable vape shop might be the starting point for the switch, but understanding the specific mechanisms through which nicotine and vaping aerosol interact with glucose metabolism and insulin function should inform both the decision to switch and how vaping is used once the switch is made.

Diabetes, Smoking and the Compounded Risk

Smoking is a recognised independent risk factor for the development of type 2 diabetes, with smokers having approximately 30–40% higher risk of developing the condition than non-smokers. Among people who already have diabetes — both type 1 and type 2 — smoking significantly worsens glycaemic control, accelerates the development of micro and macrovascular complications, and increases all-cause mortality substantially above the baseline elevated by diabetes alone. The mechanisms are multiple and interacting, which is why the effects are so pronounced even in populations with already elevated baseline risk.

For people with diabetes who are current smokers, the harm reduction argument for switching to a less harmful nicotine delivery method is stronger than average — because the additive risk of smoking on top of diabetes-related cardiovascular and microvascular disease is so significant. However, the specific metabolic effects of nicotine itself, independent of combustion, are relevant and worth understanding before assuming that vaping is metabolically neutral.

Nicotine and Insulin Resistance: The Mechanism

Nicotine has direct effects on glucose metabolism through several converging pathways. The primary mechanism is catecholamine-mediated: nicotine stimulates the adrenal medulla to release adrenaline (epinephrine) and noradrenaline (norepinephrine), activating the sympathetic nervous system. This sympathoadrenal response suppresses insulin secretion from pancreatic beta cells (via alpha-2 adrenergic receptor activation) and simultaneously stimulates glucagon secretion and hepatic glucose output. The net effect is an acute rise in blood glucose following nicotine use.

A second mechanism involves adipose tissue. Nicotine promotes the release of free fatty acids from adipocytes through lipolysis. Elevated circulating free fatty acids independently reduce insulin sensitivity in muscle and liver through mechanisms involving lipid accumulation in insulin-sensitive tissues (the fatty acid-induced insulin resistance pathway, involving DAG-PKC signalling). In people with existing insulin resistance — particularly those with type 2 diabetes — this additional nicotine-mediated pathway compounds pre-existing metabolic dysfunction.

A third mechanism involves direct effects on the pancreatic beta cell. Chronic nicotine exposure activates nicotinic acetylcholine receptors on pancreatic islet cells, and sustained stimulation of these receptors has been associated with impaired beta cell function over time. This is of particular concern in type 1 diabetes where residual beta cell function is limited, and in late-stage type 2 diabetes where beta cell mass is already compromised.

Key clinical implication: nicotine — regardless of delivery method — acutely raises blood glucose and insulin requirements in people with diabetes. For insulin-dependent diabetics, this means that vaping sessions can produce measurable glucose excursions that may require insulin dose adjustment. This is not a reason to continue smoking, but it is a reason to discuss vaping with a diabetes care team before and during the switch.

Comparing Vaping to Smoking in Diabetes: Where the Evidence Points

The comparison between smoking and vaping in the context of diabetes metabolism is complex because smoking produces nicotine-mediated metabolic effects plus additional independent effects from combustion toxins. Carbon monoxide impairs haemoglobin oxygen-carrying capacity, worsening tissue hypoxia in a population already at high risk of microvascular ischaemia. Reactive oxygen species from cigarette smoke generate oxidative stress that directly damages insulin signalling pathways. Inflammation from chronic smoke exposure elevates cytokines (particularly TNF-alpha and IL-6) that are independently associated with insulin resistance.

Vaping eliminates all three of these additional mechanisms. The nicotine-specific metabolic effects remain, but the amplifying effects of combustion toxins are removed. Studies examining HbA1c as a marker of glycaemic control over time in smokers versus vapers with diabetes are limited, but the mechanistic evidence strongly supports the expectation that switching from smoking to vaping should improve long-term glycaemic control by removing the additional hyperglycaemic and insulin-resistance pathways attributable to combustion products specifically.

Propylene Glycol, Vegetable Glycerin and Glucose Metabolism

Beyond nicotine, the base components of e-liquid — propylene glycol (PG) and vegetable glycerin (VG) — are themselves metabolically relevant substances, though at the exposure levels typical of vaping their direct metabolic impact is modest. Propylene glycol is a glucose precursor in the liver (it enters gluconeogenesis via the methylglyoxal pathway at high doses) but at ambient concentrations from vaping aerosol inhalation, systemic PG exposure is far below any threshold for gluconeogenic contribution. Vegetable glycerin is metabolically equivalent to glycerol — a three-carbon sugar alcohol that is a minor gluconeogenic substrate. Again, at inhalation exposure levels, direct contribution to blood glucose is negligible.

The more relevant concern for people with diabetes and heavily sweetened e-liquids is that sucralose and other non-nutritive sweeteners in flavoured liquids have been debated in the context of their effects on gut microbiome composition and incretin signalling. While the evidence from vaping-specific exposure is absent, the broader literature on non-nutritive sweetener ingestion and glucose regulation is genuinely mixed and warrants awareness for people with diabetes who use heavily sweetened liquids extensively.

Wound Healing and Microvascular Complications

Nicotine-mediated vasoconstriction is of particular clinical significance in diabetes, where microvascular disease already compromises peripheral blood flow. The combination of diabetic microangiopathy and nicotine-induced vasoconstriction creates a compounded impairment of tissue oxygenation in the extremities that is directly relevant to wound healing and to the risk of diabetic foot ulceration. Studies in diabetic smokers show dramatically elevated rates of wound complications compared to non-smoking diabetics; the relative contribution of nicotine versus combustion toxins to this risk is not fully disaggregated in the literature.

The practical guidance for diabetics who vape — as opposed to smoking — is that the combustion toxin contribution to vascular damage is removed, but the nicotine-mediated vasoconstriction effect at the peripheral level persists. For diabetics with established peripheral vascular disease or neuropathy, this is a relevant consideration that should be discussed with a diabetologist or vascular specialist as part of any conversation about harm reduction strategies.

Practical Guidance for Diabetic Vapers

• Inform your diabetes care team that you vape and provide details of the nicotine concentration and frequency of use. This is medically relevant information that affects glycaemic management.
• Monitor blood glucose more closely in the first weeks after switching from smoking to vaping — the change in nicotine delivery kinetics may alter your established glycaemic patterns, and insulin-dependent diabetics may need dose adjustment.
• Use the lowest nicotine concentration that prevents a return to smoking. Lower nicotine exposure produces less sympathoadrenal activation and less acute glucose elevation per use session.
• Avoid vaping immediately before or after meals if glycaemic variability is a concern — the acute glucose-raising effect of nicotine adds to postprandial glucose excursion.
• Progress toward nicotine cessation as a long-term goal — complete nicotine abstinence eliminates the metabolic effects described above entirely and should be supported by your diabetes team as part of long-term condition management.